Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERANT: Rosuvastatin/Ezetimibe vs Atorvastatin/Ezetimibe after Coronary Stenting
NCT05910476Phase 4Active, not recruiting
- Sponsor
- Yonsei University
- Start
- May 2023
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronary artery disease (CAD) and dyslipidemia comparing Rosuvastatin/Ezetimibe 20/10mg with Atorvastatin/Ezetimibe 40/10mg (2 arms). Primary endpoints: Percentage of statins changed at 12 months and Rate at which LDL cholesterol remains below 55 mg/dL at 12 months. Started May 2023; status: active, not recruiting.
02
Drugs
rosuvastatinatorvastatinezetimibe
03
Conditions
coronary artery disease (CAD)dyslipidemia
Beyond the preview
Go deeper on NCT05910476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910476.